Insulin Glargine vs Flibanserin: side-by-side comparison
Insulin Glargine (Long-acting insulin analogue) and Flibanserin (Multifunctional serotonin agonist/antagonist (HSDD)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Insulin Glargine | Flibanserin |
|---|---|---|
| Therapeutic class | Long-acting insulin analogue | Multifunctional serotonin agonist/antagonist (HSDD) |
| CAS | 160337-95-1 | 167933-07-5 |
| ATC | A10AE04 | G02CX02 |
| Molecular weight | 6063 Da | 390.4 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Insulin Glargine and Flibanserin share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Insulin Glargine acts by a different mechanism than Flibanserin, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Insulin Glargine: Insulin glargine binds the insulin receptor with similar affinity to human insulin, activating intracellular signalling that increases glucose uptake in muscle and adipose tissue, suppresses hepatic glucose production an… Flibanserin: Flibanserin acts as a serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist, with additional effects on dopamine and norepinephrine signalling.
Indications compared
Insulin Glargine: Insulin glargine is approved as basal insulin therapy in adults and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus when oral or non-insulin injectable therapy is insufficien… Flibanserin: Flibanserin is approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women — specifically, acquired (not lifelong) and generalised (not situational) HSDD, with personal distress, not better ex…
Safety profile
Insulin Glargine: Hypoglycaemia is the most important adverse effect of any insulin and can be severe in case of missed meals, prolonged exercise, alcohol intake or interaction with other glucose-lowering agents. Flibanserin: Common adverse effects include dizziness, somnolence, nausea, fatigue and dry mouth.
Frequently asked questions
Is Insulin Glargine better than Flibanserin? ▾
Insulin Glargine and Flibanserin are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Insulin Glargine and Flibanserin be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Insulin Glargine
Products with Flibanserin
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.